skip to content

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.